Development of mismatch amplification mutation assay (MAMA) for the rapid differentiation of Mycoplasma gallisepticum K vaccine strain from field isolates

Bekő, Katinka and Kovács, Áron Botond and Kreizinger, Zsuzsa and Marton, Szilvia and Bányai, Krisztián and Bánáti, László and Catania, Salvatore and Bradbury, Janet and Lysnyansky, Inna and Olusola, Martins Olaogun and Gyuranecz, Miklós (2020) Development of mismatch amplification mutation assay (MAMA) for the rapid differentiation of Mycoplasma gallisepticum K vaccine strain from field isolates. AVIAN PATHOLOGY, 49 (4). pp. 317-324. ISSN 0307-9457

Preview

Text Development of mismatch amplification mutation 2020.pdf - Accepted Version Download (1MB) | Preview

Abstract

Mycoplasma gallisepticum causes respiratory diseases and reproduction disorders in turkeys and chickens. The infection has considerable economic impact due to reduced meat and egg production. Because elimination programmes are not feasible in a large number of poultry farms, vaccination remains the only effective measure of disease control. Differentiating vaccine strains from field isolates is necessary in the control of vaccination programmes and diagnostics. The aim of this study was to develop a polymerase chain reaction based mismatch amplification mutation assay (MAMA) for the discrimination of K vaccine strain (K 5831, Vaxxinova Japan K.K.). After determining the whole genome sequence of the K strain, primers were designed to detect seven different vaccine-specific single nucleotide polymorphisms. After evaluating preliminary results, the MAMA-K-fruA test detecting a single guanine-adenine substitution within the fruA gene (G88A) was found to be the most applicable assay to distinguish the K vaccine strain from field isolates. The detected K strain-specific single nucleotide polymorphism showed genetic stability after serial passage in vitro, but this stability test should still be evaluated in vivo as well, investigating a large number of K strain re-isolates. The MAMA-K-fruA assay was tested on a total of 280 culture and field samples. The designed assay had 102 and 103 template copy number/µl sensitivity in melt-curve analysis based and agarose-gel based assays, respectively, and showed no cross reaction with other avian Mycoplasma species. The new MAMA provides a time- and cost-effective molecular tool for the control of vaccination programmes and for diagnostics.

Actions (login required)

Edit Item